A multiantigenic protein vaccine provides partial protection against chronic toxoplasma infection in mice

VICTORIA PASTOR; ARCÓN, NADIA; I FENOY; V SANCHEZ; A GOLDMAN; IVAN MARCIPAR; V MARTÍN

Mar del Plata

Congreso; Reunion Anual Biociencias 2022- reunion SAI FAIC; 2022

Toxoplasmosis is a disease that affects 30% of the world´s population. At present, there are no pharmacological treatments that eliminate the parasite or vaccines that confer protection to the host. The aim of the present work was to study the immunogenicity of vaccines based on the mix of recombinant proteins combined with the new cage-like particle adjuvant (ISPA). METHODS: C57BL/6 mice were intradermally immunized 2 or 3-times with a 2-week interval with different combinations of rGRA7 (G), rTgPF (T) or rROP2 (R) proteins along with ISPA adjuvant. Control groups received ISPA or PBS. Fourteen-days later, mice were orally challenged with T. gondii cysts and after one month, brain cyst numbers were determined under optical microscope. In vitro antigen-specific responses were characterized in sera and spleens (S) from vaccinated mice.RESULTS: Significant reduction in brain parasite load was obtained with the mix of the three proteins R+G+T+ISPA (p